Second Annual Conference on Vaccine Research

Centers for Disease Control and Prevention

National Foundation for Infectious Diseases

National Institute of Allergy and Infectious Diseases

International Society for Vaccines

Center for Biologics Evaluation and Research, FDA

Children's Vaccine Initiative

Albert B. Sabin Vaccine Institute at Georgetown University

World Health Organization

Sunday, March 28, 1999

7:00 - 9:00 a.m. Registration

8:30 a.m. Continental Breakfast

9:00 a.m. Welcome and Introductions
William J. Martone, M.D.
National Foundation for Infectious Diseases

9:05 a.m. Introduction of Keynote Speaker
Peter L. Nara, D.V.M., Ph.D.
Biological Mimetics, Inc.
International Society for Vaccines

Keynote Address

9:10 a.m. Keynote Address: Immune Memory and the Recall Response Peter C. Doherty, Ph.D.
St. Jude's Children's Hospital

9:50 a.m. Questions and Answers

Symposium 1: Vaccines for Major World Diseases: AIDS, Malaria, Tuberculosis

Moderators:
Paul-Henri Lambert, M.D.
World Health Organization
Philip K. Russell, M.D.
The Johns Hopkins University School of Hygiene and Public Health

10:00 a.m. Introduction to Vaccines for Major World Diseases
Paul-Henri Lambert, M.D.
World Health Organization
Philip K. Russell, M.D.
The Johns Hopkins University School of Hygiene and Public Health

10:05 a.m. Biographical Tribute to the Career of Mary Lou Clements-Mann
Myron M. Levine, M.D., D.T.P.H.
University of Maryland

10:15 a.m. Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences: Progress, Obstacles and Future Priorities in HIV Vaccine Development
Margaret I. (Peggy) Johnston, Ph.D.
National Institutes of Health

10:45 a.m. Questions and Answers

10:50 a.m. Tribulation or Triumph: Are We Close to a Successful Malaria Vaccine?
Colonel W. Ripley Ballou, M.D.
Walter Reed Army Institute of Research

11:20 a.m. Questions and Answers

11:25 a.m. Reaping the Fruits of Biotechnology: Development of Better Tuberculosis Vaccines
Douglas B. Young, Ph.D.
Imperial College School of Medicine

11:55 a.m. Questions and Answers

12:00 p.m. Lunch

Submitted Presentations 1

1:30 p.m. Submitted Presentations 1

SEROPROTECTIVE LEVELS AGAINST LYME DISEASE ACHIEVED AFTER IMMUNIZATION WITH LYMERIX LYME DISEASE VACCINE (RECOMBINANT OspA) - D. L. Parenti
A SINGLE BLINDED RANDOMISED TRIAL COMPARING TWO ADULT ACELLULAR PERTUSSIS VACCINES WITH A LICENSED ADULT DIPHTHERIA-TETANUS VACCINE (ADT) - F.M. Tumbull
NASOPHARYNGEAL CARRIAGE OF STREPTOCOCCUS PNEUMONIAE IN INFANTS GIVEN PRIMARY AND BOOSTER DOSES OF 7 -VALENT PNEUMOCCOCAL CONJUGATE VACCINE - S. Yeh
RECOMBINANT POLYVALENT VACCINE AGAINST MELIODOSIS AND GLANDERS - N.N. Kislichkin
TOWARDS A VACCNE FOR SHIGA TOXIN-PRODUCING E. COLI (STEC): PROTECTION AGAINST HEMORRAGIC COLITIS IN AN ANIMAL MODEL BY IMMUNIZATION WITH A RABBIT ENTEROPATHOGENIC E. COLI (REPEC) EXPRESSING TRUNCATED INTIMIN - T. Agin
STUDY OF A NASAL VACCINE AGAINST NEISSERIA MENINGITIDIS B IN A MOUSE MODEL - E.N. De Gaspari

3:00 p.m. Coffee Break

Submitted Presentations 2

1:30 p.m. Submitted Presentations 2

TOPICAL APPLICATION OF ANTIGEN TO THE SKIN SURFACE RAPIDLY INDUCES ANTIGEN SPECIFIC CD4+ T CELL RESPONSES - T.M. Scharton-Kersten
DEVELOPMENT OF AN EDIBLE VACCINE TO SWINE TRANSMISSIBLE GASTROENTERITIS VIRUS USING ANTIGENS EXPRESSED IN MAIZE SEED - Joseph M. Jilka
CELLULAR SELECTION OF HUMAN ROTATAVIRUS ENTEROTOXIN GENE VARIANTS IN CELL CULTURE: A POTENTIAL STRATEGY TO OBTAIN NONTOXIC FORMS OF TOXIC GENES FOR SUBUNIT VACCINE APPLICATIONS - C.D. Atreya
BOTH ANTIBODY-DEPENDENT AND -INDEPENDENT PROTECTION ARE STIMULATED AFTER INTRANASAL IMMUNIZATION OF MICE WITH INACTIVATED ROTAVIRUS PARTICLES - R.L. Ward
A NEW VACCINE STRATEGY: ENHANCEMENT OF T CELL RESPONSES BY RECRUITING CD26 TO THE TCR/MHC COMPLEX WITH A HIGH-AFFINITY CD26 LIGAND COVALENTLYATTACHED TO COGNATE T CELL PEPTIDE EPITOPES - C. Plant
STRATEGY FOR ISOLATION OF MEASLES VACCINE VIRUS (MRV) PROCESSED PEPTIDES FROM CLASS II HLA-DR4 ALLELES - I.G. Ovsyannikova

3:00 p.m. Coffee Break

Symposium 2: Antigen Processing and Presentation

Moderators:
Brian W.J. Mahy, Ph.D., Sc.D.
Centers for Disease Control and Prevention
Howard R. Six, M.D.
Pasteur Mérieux Connaught

3:30 p.m. Molecular Mechanisms of MHC Class I-Restricted Antigen Processing
Peter Cresswell, Ph.D.
Howard Hughes Medical Institute
Yale University School of Medicine

4:05 a.m. Questions and Answers

4:10 p.m. Immune Surveillance of Viral Infections
Kenneth L. Rock, M.D.
University of Massachusetts Medical School

4:45 a.m. Questions and Answers

4:50 p.m. Modulation of Proteasome Structure and Function for Antigen Processing
John J. Monaco, Ph.D.
Howard Hughes Medical Institute
University of Cincinnati

5:25 a.m. Questions and Answers

5:30 p.m. Adjournment

Opening Reception

6:00 p.m. - 7:30 p.m.

Monday, March 29, 1999

7:00 a.m.	Poster Set-Up and Registration
8:00 a.m.	Continental Breakfast
Symposium 3: Therapeutic Vaccines
	Moderators: Jacques Banchereau, Ph.D. Baylor Institute for Immunology Research N. Regina Rabinovich, M.D. National Institute of Allergy and Infectious Diseases
8:30 a.m.	Dendritic Cells as Vectors for Tumor Vaccines Jacques Banchereau, Ph.D. Baylor Institute for Immunology Research
8:55 a.m.	Questions and Answers
9:00 a.m.	Induction of Anti-Tumor Immunity by Chemokine-scFv Fusions in Murine B Cell Lymphomas Arya Biragyn, Ph.D. National Cancer Institute
9:25 a.m.	Questions and Answers
9:30 a.m.	Characterization of Tumor Vaccines During Product Development Raj K. Puri, M.D., Ph.D. Food and Drug Administration
9:55 a.m.	Questions and Answers
10:00 a.m.	CpG Immunostimulatory Sequences for Therapeutic Vaccines Arthur M. Krieg, M.D. University of Iowa College of Medicine Iowa City VA Medical Center CpG ImmunoPharmaceuticals, Inc.
10:25 a.m.	Questions and Answers
10:30 a.m.	Coffee Break
	Submitted Presentations 3
11:00 a.m.	Submitted Presentations 3
	BIVALENT ENVELOPE VACCINES (AIDSVAX™) EVALUATED FOR EFFICACY AGAINST BLOOD-BORNE ANO SEXUALLY TRANSMITTED HIV-1 IN THAILAND AND NORTH AMERICA - D.P. Francis TESTING TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE CANDIDATES IN HUMAN SUBJECTS BY FACTORIAL DESIGN - W. Sun EVALUATION OF THE SAFETY, IMMUNOGENICITY, AND VIRUS SHEDDING OF A INTRANASAL BOVINE PARAINFLUENZA VIRUS TYPE 3 (PIV3) VACCINE IN INFANTS - P. Greenberg PHASE I SAFETY AND IMMUNOGENICITY TRIAL OF A RECOMBINANT HEPATITIS E VIRUS VACCINE - R. Kuschner
12:00 p.m.	Lunch
	Submitted Presentations 4
1:30 p.m.	Submitted Presentations 4
	CHIMERIVAX - NOVEL, LIVE ATTENUATED GENETICALLY-ENGINEERED VACCINES AGAINST HETEROLOGOUS FLAVIVIRUSES, BASED ON YELLOW FEVER (YF) 17D VACCINE - T.P. Monath EFFECTIVENESS OF INACTIVATED HANTAAN VIRUS VACCINE (HANTAVAX) AGAINST HEMORRHAGIC FEVER WITH RENAL SYNDROME: A POPULATION-BASED, CASE-CONTROL STUDY IN KOREAN SOLDIERS - You-Choel Shin BOOSTER DOSES OF MEASLES VACCINE IN SCHOOLCHILDREN: RESPONSES TO DIFFERENT VACCINE STRAINS AND THE AEROSAL ROUTE - A. Dilraj REACTOGENICITY AND IMMUNOGENICITY OF COMBINED MEASLES-MUMPS-RUBELIA-VARICELLAA VACCINE, AND MEASLES-MUMPS-RUBELLA VACCINE ALONE OR WIIH VARICELLA VACCINE AS A SINGLE INJECTION EXTEMPORANEOUS MIX - T. Nolan ENHANCE HUMORAL RESPONSES TO HCV ENVELOPE IN DNA IMMUNIZATION BY PROTEIN BOOST - Guo-Jun Hu REVISITING WHOLE-INACTlVATED HIV-1VACCINES: RETENTION OF GPl20 AND ENHANCED ANTIGENICITY OF CONFORMATION-DEPENDENT NEUTRALIZATION EPITOPES - K. Grovit-Ferbas
3:00 p.m.	Coffee Break
	Submitted Presentations 5
1:30 p.m.	Submitted Presentations 5
	GELATIN IN VACCINES AS A POSSIBLE CAUSE OF ANAPHYLAXIS - V. Pool THE SAFETY OF HEPATITIS B VACCINE IN ADULTS - R. Chen CLINICAL STUDIES OF THE TOLERANCE OF INTRAMUSCULAR QS-21 FORMULATIONS - C. Kensil DOES INFLUENZA VACCINATION PROTECT CHILDREN AGAINST EXACERBATION OF ASTHMA? - P. Kramarz IS IT IMMUNOLOGICALLY FEASIBLE TO DELAY ADULT DIPHTHERIA/TETANUS BOOSTER IMMUNIZATION TO AGE 50? - David W. ScheifeIe BIOSYNTHETIC MODIFICATION OF A LIPID-A ASSOCIATED TOXICITY AND ADJUVANT ACTIVITY IN NEISSERIA MENINGITIDIS: IMPLICATIONS FOR VACCINE DEVELOPMENT - Peter van der Ley
3:00 p.m.	Coffee Break
Symposium 4: Genetic Determinants of Vaccine Immune Response
	Moderators: Janardan P. Pandey, Ph.D. Medical University of South Carolina Gregory A. Poland, M.D. Mayo Clinic and Foundation
3:30 p.m.	An Overview of the Genetic Basis for Variations in the Immune Response to Vaccines Gregory A. Poland, M.D. Mayo Clinic and Foundation
4:05 p.m.	Questions and Answers
4:10 p.m.	Genetic Polymorphisms and Vaccine Immunity Janardan P. Pandey, Ph.D. Medical University of South Carolina
4:45 p.m.	Questions and Answers
4:50 p.m.	Genetic Regulation of Immunoglobulin G Response to Pneumococcal Capsular Polysaccharide Daniel M. Musher, M.D. Houston VA Medical Center Baylor College of Medicine
5:25 p.m.	Questions and Answers
5:30 p.m.	Adjournment
Poster Session and Reception
	DIFFERENTIAL INDUCTION OF IL-8 AND MIP1-BETA BY BCG - C. Jagannath CLONING, EXPRESSION, AND IMMUNE RESPONSES T0 THE 65 KILODALTON HEAT SHOCK PROTElN OF M. AVIUM - M. .V. Nagabhushanam A LARGE COMMUNITY TRIAL TD EVALUATE THE EFFICACY OF A SECOND BCG DOSE IN SCHOOLCHILDREN AGAINST TUBERCULOSIS AND LEPROSY IN BRAZIL - Mauricio L. Barreto A NASAL VACCINE INDUCED BETTER ANTIBODY RESPONSES WHEN GIVEN AS REPEATED SMALL DOSES RATHER THAN AS ONE SINGLE LARGE DOSE - B. Haneberg A NASAL OUTER MEMBRANE VESICLE (OMV) VACCINE CAN INDUCE IMMUNOLOGICAL MEMORY WITH STRONG BOOSTER ANTIBODY RESPONSES - B. Haneberg IDENTIFICATION OF A NOVEL OUTER MEMBRANE PROTEIN OF NEISSERIA MENINGITIDIS AND ITS POTENTIAL AS A VACCINE CANDIDATE - L.M.C. Coutinho TRIVALENT SHIGELLAE LIPOPOLYSACCHARIDE VACCINE - P.G. Aparin INVESTIGATION OF CELLULAR AND HUMORAL IMMUNE RESPONSES TO WHOLE CELL AND ACELLULAR PERTUSSIS VACCINES - Catpagavalli Canthaboo B CELL EFFECTOR RESPONSES IN THE GASTRIC ANTRUM AND DUODENUM FOLLOWING HELIOCOBACTER PYLORI ADJUVANTED WITH LTR192G IN H. PYLORI SERONEGATIVE (HP-) INDlVIDUALS - G.A. Losonsky DEVELOPMENT OF A DNA VACCINE AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) - J.P. Senna INVASIVE PNEUMOCOCCAL INFECTIONS IN CANADIAN CHILDREN, 1991-8: IMPLICATIONS FOR NEW VACCINATION STRATEGIES - David W. Scheife1e, DIPHTHERIA AND POLIOMYELITIS IMMUNITY IN THE NETHERLANDS - H.E. de Melker RE-VACCINATING CHILDREN PREVIOUSLY VACCINATED WITH EDMONSTON-ZAGREB (EZ) MEASLES VACCINE - M. Khalil EXPRESSION OF THE RECOMBINANT DENGUE 4 VIRUS TRUNCATED E GLYCOPROTElN MADE IN PICHIA PASTORIS AND EVALUATION OF THE IMMUNE RESPONSE INDUCED IN MICE - R. Rodriguez EXPRESSION OF TRUNCATED DENGUE-2 PROTEIN BY A DNA VACCINE CANDIDATE IS DEPENDENT OF ITS SIGNAL PEPTIDE BUT INDEPENDENT OF THE WHOLE PRM PROTEIN - R. Occazionez DENGUE-2 DNA VACCINE CANDIDATE EXPRESSING A TRUNCATED E PROTEIN PROLONGS ITS MICE SURVIVAL AFTER CHALLENGE WITH A VIRULENT STRAIN - R. Occazionez ATYPICAL IMMUNE RESPONSES AMONG DENGUE VACCINE RECIPIENTS ATTRIBUTABLE TO OCCULT YELLOW FEVER EXPOSURE - N. Kanesa-thasan HIGH AVIDITY VIRUS SPECIFIC-IGG ANTIBODY RESPONSE AFTER INAVTIVATED HANTAAN VIRUS VACCINE IMMUNIZATION AND ITS UTILITY - Min-Ja Kim SAFETY AND IMMUNOGENICITY OF A LIVE-ATTENUATED, MUTAGENIZED RIFT VALLEY FEVER VACCINE IN HUMANS - P.R. Pittman DEVELOPMENT OF DNA VACCINES DIRECTING ANTIGENS TO ALTERNATIVE CELLULAR PROCESSING PATHWAYS AND THEIR EFFECT ON THE IMMUNE RESPONSE - S. Cohen NUCLEIC ACID VACCINATION AGAINST HEPATITIS B SURFACE ANTIGEN IN MICE - A. Karami THE ATTENUATION PHENOTYPE OF LIVE, TEMPERATURE-SENSITIVE (TS) VACCINE STRAINS AT RESTRICTIVE TEMPERATURES IS NOT ASSOCIATED WITH ENHANCED INTERFERON SYNTHESIS OR INCREASED-SENSITIVITY TO TYPE 1 INTERFERONS (IFNS) - D.A. Loveys RESTRICTED REPLICATION OF A CHIMERIC VIRUS FOR INDUCING PROTECT IMMUNITY AGAINST SIV INFECTION - T. Matano ALTERED PATTERNS OF SIVMAC251 INFECTION AFTER DNA VACCINATION IN MACAQUES - Pbilippe Lena THE CYTOPLASMIC TAIL OF CD86 COSTIMULATORY MOLECULE INVOLVED IN ANTI-HIV CTL RESPONSES DURING DNA VACCINATION - B. Monzavi-Karbassi EFFECT OF PROMOTER STRENGTH ON CELLULAR AND HUMORAL IMMUNE RESPONSES ELICITED BY HIV-l MULTIGENIC DNA VACCINES - T.A. Galvin HUMORAL AND CELLULAR IMMUNE RESPONSE ELICITED BY HIV-ENV DNA CONSTRUCTS IN MICE - Alka Arora HIV-1 VACCINE TRIALS AT THE VACCINE TRIAL CENTRE (VTC) IN BANGKOK - Punnee Pitisuttihum INCREASING HIV INCIDENCE IN A HIGH RISK HETEROSEXUAL POPULATION SUITABLE FOR VACCINE TRIALS IN HONDURAS - W. Kiaskala THE INFLUENCE OF CHANGES IN KNOWLEDGE OF VACCINE TRIAL CONCEPTS ON WILLINGNESS TO PARTICIPATE IN VACCINE TRIALS OVER 18 MONTHS FOLLOW-UP IN THE VACCINE PREPAREDNESS STUDY OF THE HIVNET - W.R. Lenderking FEASIBILITY OF EFFICACY TRIALS ON HIV VACCINES: COHORT BELA VISTA - Jose R. Carvalheiro CLINICAL TRIALS WITH CANDIDATE HIV/AIDS VACCINES IN BRAZIL - Jose R. Carvalheiro RESULTS OF A HIV INCIDENCE COHORT OF HOMO/BISEXUAL MEN IN PREPARATION FOR FUTURE CLINICAL TRIALS IN BALA HORIZONTE, BRAZIL - 4 TEAR REPORT OF THE PROJECT HORIZONTE HIV VACCINES CLINICAL TRIALS IN "DEVELOPING" COUNTRIES: THE FALLACY OF URGENCY OR ETHICS VS. ECONOMICS - Dirceu B. Greco IMMUNIZATION OF BALBC MICE WITH A PLASMID CODING FOR A HYBRID MSP1.19-HBSAG PROTEIN INDUCES PARTIAL PROTECTION AGAINST LETHAL P. CHABAUDI MALARIA BLOOD STAGE INFECTION - G. Wunderlich MOUSE MODEL FOR GENITAL TRACT ASCENDING INFECTION BY CHLAMYDIA TRACHOMATIS SEROVAR D AND ASSESMENT BY DNA VACCINATION - R. Cevenini DEVELOPMENT OF A VACCINE AGAINST COCCIDIOIDOMYCOSIS - G.W. Rutherford PROTEIN AGAINST BOVINE VIRAL DIARRHEA VIRUS (BVDV) OF CALVES VACCINATED WITH A BOVINE HERPESVIRUS-l (BHV.l ).BVDV RECOMBINANT - H. J. Swan INVESTIGATION OF THE PROTECTIVE CAPACITY OF COMMERCIAL VACCINES AGAINST CHALLENGE OF FOALS WITH EQUINE HERPESVIRUS-1 - C.C. Breathnach LIVE ATTENUATED SALMONELLAE AS CARRIERS IN THE CONSTRUCTION OF ORAL MULTIVALENT VACCINES FOR DOGS - Jose A. Chabalgoity CLONING AND EXPRESSION OF CHROMOSOMAL DNA OF VACCINE STRAIN STI OF B. ANTHRACIS - N.N. Kislichkin PROTECTION STUDIES FOLLOWING BROCHOPULMUNARY AND INTRAMUSCULAR IMMUNIZATION WITH YERSINIA PESTIS RECOMBINANT SUBUNIT VACCINES ENTRAPPED IN BIODEGRADABLE MICROPARTICLES - J.E. Eyles NON-INVASIVE IMMUNIZATION STRATEGIES FOR PLAGUE - H.O. Alpar DEVELOPMENT OF AN IMMUNOTHERAPEUTIC VACCINE STRATEGY TO BVPASS THE T-HELPER CELL DEFECT IN HIV-1 INFECTED PERSONS AND GENERATE SYSTEMIC AND MUCOSAL IMMUNE RESPONSES - Basil Golding AUTOVACCINES AS THERAPEUTIC INSTRUMENTS TO TREAT CHRONIC BACTERIAL INFECTIONS - O. Nolte A GROUP B COXSACKIEVIRUS IS ATTENUATED BV SITE-SPECIFIC MUTATIONS WITHIN A COMPLETELY CONSERVED 5 NUCLEOTIDE SEQUENCE IN THE 5' NON-TRANSLATED REGION - S. Willian APPLICATION OF BIOINFORMATICS AND PROTEOMICS FOR IDENTIFICATION OF BACTERIAL GENE PRODUCTS AS POTENTIAL VACCINE CANDIDATES - Deb N. Chakravarti HARE: AN IMPROVED MEASURE OF EFFICACY FOR PHASE III HIV-l VACCINE TRIALS - K. Desai RATES OF MEDICALLY ATTENDED INJECTION SITE REACTIONS ASSOCIATED WITH ADULT VACCINATIONS - M.M. Braun SAFETY AND TOLERABILITY OF VARYING DOSES OF INFLUENZA VACCINE ADMINISTERED BY JET INJECTOR (JI) VS. NEEDLE AND SYRINGE (N&S) - L.A. Jackson PREDICTING THE NEUROVIRULENCE POTENTIAL OF MUMPS VIRUS VACCINE STRAINS FOR THE HUMAN CNS - S.A. Rubin EDIBLE VACCINE AGAINST HBC FROM TRANSGENIC PLANTS - L. Richter INDUCTION OF POTENT MUCOSAL ANTIBODY RESPONSES IN THE COMMON MUCOSAL IMMUNE SYSTEM BY RSV ICOMS AND RSV/GP120 ICOMS - Ke-Fei Hu INTRANASAL VACCINATION OF MICE WITH ROTAVIRUS VP6 AND LT(RI92G) INDUCED PROTECTION AGAINST INFECTION BV AN ANTIBODV- AND B-CELL INDEPENDENT MECHANISM A.H. - C. Choi USE OF THE SHIGELLA INVASIN COMPLEX AS A NEW SUBUNIT VACCINE AND MUCOSAL ADJUVANT - E.V. Oaks SKIN ADMINISTRATION OF POWDERED VACCINES IS A SAFE AND EFFECTVE WAV OF VACCINATION - D. Chen EVALUATION OF HUMAN CELLULAR IMMUNE RESPONSES AGAlNST HEPATITIS B FOLLOWING PARTICLE-MEDIATED EPIDERMAL DNA DELIVERY - Deborah Fuller PARTICLE-BASED INTRACELLULAR CO-DELIVERY OF DNA WITH A SAPONIN TYPE ADJUVANT ENHANCES SPECIFIC CELLULAR IMMUNE RESPONSES IN MICE TH1 TYPE CYTOKINES, IN PARTICULAR IL-12 CONJECTION DRIVES ANTIGEN-SPECIFIC TH1 TYPE CD4+ T CELLS, RESULTING IN ENHANCED PROTECTION FROM LETHAL HERPES SIMPLEX VIRUS (HSV)- 2 CHALLENGE - J.-I. Sin THE IMPORTANCE OF IL-12 IN PROTECTIVE IMMUNITY AND IMMUNIZATION AGAINST THE PROTOZOAN, LEISHMANIA CHAGASI - M.E. Wilson DTH RESPONSES OF MICE IMMUNIZED WITH RECOMBINANT PROTEINS USING TWO CHITOSAN-BASED ADJUVANTS - P.G. Seferian IN VIVO EXPRESSION AND IMMUNOADJUVANCY OF A MUTANT OF HEAT-LABILE ENTEROTOXIN OF ESCERICHIA COLI IN VACCINE AND VECTOR STRAINS OF VIBRIO CHOLERAE - E.T. Ryan THE BACTEROIDES FRAGILIS METALLOPROTEASE ENTEROTOXlN, FRAGILYSIN, IS A MUCOSAL ADJUVANT - R.R. Vines ANALYSES OF HOST RESPONSES RELEVANT TO MEASLES VIRUS-INDUCED IMMUNOSUPPRESSION - H. Okada
5:30 p.m. - 7:30 p.m.

Tuesday, March 30, 1999

8:00 a.m. Registration and Continental Breakfast

Symposium 5: Clinical Trials in Developing Countries: What Are the Issues?

Moderators:
José Esparza, M.D., Ph.D.
UNAIDS
Myron M. Levine, M.D., D.T.P.H.
University of Maryland

9:00 a.m. Responsibilities of Sponsors After Successful Phase III Efficacy Trials
William P. Hausdorff, Ph.D.
Wyeth-Lederle Vaccines

9:20 a.m. Questions and Answers

9:30 a.m. Post-Licensure Selective Vaccination and Surveillance Programs Can Provide Controlled Effectiveness Data
Rosanna Lagos, M.D.
Centro para Vacunas en Desarrollo, Chile
Hospital Roberto Del Rio

9:55 a.m. Questions and Answers

10:00 a.m. AIDS Exceptionalism in the Vaccine Arena: Additional Obstacles for HIV Vaccine Trials
José Esparza, M.D., Ph.D.
UNAIDS

10:25 a.m. Questions and Answers

10:30 a.m. Coffee Break

Submitted Presentations 6

11:00 a.m. Submitted Presentations 6

INDUCTION OF IMMUNE RESPONSES IN INDIVIDUALS SERONEGATIVE FOR HIV-1 FOLLOWING ADMINISTRATION OF ENV/REV HIV-1 DNA VACCINES - J. Boyer
PROTECTIVE ANTIBODY RESPONSES IN MAN BY A DNA VACCINE FOR HEPATITIS B - M. Roy
IMMUNOGENICITY AND PROTECTIVE EFFICAY OF A DENGUE VIRUS TYPE 1 DNA VACCINE IN A NON HUMAN PRIMATE MODEL - K. Raviprakash
THE EFFECT OF DIFFERENT PROMOTERS AND ADJUVANTS FOR INTRAMUSCULARLY INJECTED DNA VACCINES IN CHICKENS - David Suarez

12:00 p.m. Lunch

Symposium 6: Vaccines Against Candidate Bioterrorist Agents

Moderators:
Richard J. Duma, M.D., Ph.D.
Halifax Medical Center
Colonel Charles H. Hoke, Jr., M.D., M.C.
U.S. Army Medical Research and Materiel Command

1:30 p.m. Overview of Potential Bioterrorist Biological Agents and Countermeasures
Lieutenant Colonel George W. Korch, Jr., Ph.D.
U.S. Army Medical Research Institute of Infectious Diseases

1:55 a.m. Questions and Answers

2:00 p.m. Strategies for Vaccination Against Brucellosis Colonel David L. Hoover, M.D.
Walter Reed Army Institute of Research

2:25 a.m. Questions and Answers

2:30 p.m. Viral Agents and Countermeasures: Orthopoxviruses and Filoviruses
Peter B. Jahrling, Ph.D.
U.S. Army Medical Research Institute of Infectious Diseases

2:55 a.m. Questions and Answers

3:00 p.m. Multi-Agent Vaccine Approaches for Infectious Agents
Jonathan F. Smith, Ph.D.
U.S. Army Medical Research Institute of Infectious Diseases

3:25 a.m. Questions and Answers

3:30 p.m. Adjournment

Back to NFID-SPONSORED CONFERENCES